Jazz Pharmaceuticals PLC $JAZZ Shares Acquired by Sowell Financial Services LLC

Sowell Financial Services LLC raised its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 501.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,458 shares of the specialty pharmaceutical company’s stock after acquiring an additional 11,219 shares during the quarter. Sowell Financial Services LLC’s holdings in Jazz Pharmaceuticals were worth $3,116,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in JAZZ. Bank of New York Mellon Corp increased its position in shares of Jazz Pharmaceuticals by 44.5% in the first quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock valued at $317,485,000 after acquiring an additional 517,514 shares during the last quarter. Bank of America Corp DE lifted its holdings in Jazz Pharmaceuticals by 10.9% during the 1st quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock worth $191,848,000 after purchasing an additional 99,656 shares during the last quarter. Boston Trust Walden Corp increased its position in Jazz Pharmaceuticals by 24.1% during the first quarter. Boston Trust Walden Corp now owns 488,661 shares of the specialty pharmaceutical company’s stock worth $92,381,000 after acquiring an additional 94,750 shares during the period. Systematic Financial Management LP lifted its position in Jazz Pharmaceuticals by 2.6% during the first quarter. Systematic Financial Management LP now owns 407,114 shares of the specialty pharmaceutical company’s stock worth $76,965,000 after purchasing an additional 10,237 shares during the period. Finally, Quantinno Capital Management LP raised its stake in Jazz Pharmaceuticals by 9.7% during the first quarter. Quantinno Capital Management LP now owns 191,286 shares of the specialty pharmaceutical company’s stock worth $36,163,000 after acquiring an additional 16,928 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $230.33, for a total value of $1,381,980.00. Following the completion of the transaction, the director owned 345,875 shares in the company, valued at $79,665,388.75. This trade represents a 1.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the firm’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total value of $289,128.00. Following the transaction, the executive vice president directly owned 47,671 shares of the company’s stock, valued at $11,485,850.74. This represents a 2.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 100,121 shares of company stock worth $24,855,802 in the last ninety days. Insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $215.98 on Friday. The company’s fifty day moving average price is $231.96 and its 200-day moving average price is $216.24. Jazz Pharmaceuticals PLC has a one year low of $128.80 and a one year high of $266.38. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.78 and a quick ratio of 1.58. The firm has a market capitalization of $14.02 billion, a price-to-earnings ratio of 9.00, a PEG ratio of 0.42 and a beta of 0.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.18 by ($0.47). The business had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. The company’s revenue was up 15.5% compared to the same quarter last year. During the same period last year, the business posted ($8.25) earnings per share. On average, equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 10.87 earnings per share for the current fiscal year.

Analysts Set New Price Targets

JAZZ has been the topic of several recent research reports. Needham & Company LLC lifted their target price on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, August 26th. Wells Fargo & Company upped their price target on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. TD Cowen boosted their target price on shares of Jazz Pharmaceuticals from $275.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a report on Wednesday, August 26th. Finally, Citigroup assumed coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, September 30th. They set a “buy” rating and a $325.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $292.05.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.